(Stockholm, Sweden - August 23, 2022) Stratipath, a global leader in artificial intelligence (AI)-based precision diagnostic solutions, today announced that it has released its integration with international medical imaging IT company Sectra and their digital pathology solution. This means that Sectra users can use Stratipath's solution Stratipath Breast within an already existing digital pathology workflow. The application is featured in Sectra Amplifier Marketplace and purchased directly from Stratipath.
The integration between Sectra and Stratipath will give the possibility of novel deep learning image analysis integrated into the existing digital pathology workflow. Stratipath's solution for risk stratification of breast cancers, Stratipath Breast, provides novel decision support for clinicians in the diagnostic evaluation of breast cancer.
Stratipath Breast is the first EU regulatory compliant solution for risk stratification of breast cancer using AI-based precision diagnostics to analyse cancer tissue, and enabling identification of patients with increased risk of disease progression. Based on the analysis of digital histopathology whole slide images, stained with haematoxylin and eosin (H&E), Stratipath Breast enables detection and classification of intermediate risk tumours into low- and high-risk groups, based on grade-related tumour morphology. Hereby, the results provide novel decision support to clinicians and enables precision medicine for more breast cancer patients.
Ad Statistics
Times Displayed: 3899
Times Visited: 9 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money.
In contrast to traditional molecular tests for risk stratification, AI-based risk stratification enables faster turnaround times for results, provides new information at the point of diagnosis and reduces the need for expensive molecular testing, allowing for wider use and benefit to more patients.
"Stratipath Breast offers a faster and cheaper alternative to molecular assays, allowing more patients to have access to precision diagnostics. By using Stratipath Breast, clinicians can diagnose with support from prognostic information, while reducing laboratory time and costs," says Johan Hartman, professor in pathology at Karolinska Institutet, Stockholm, and co-founder of Stratipath.
About Sectra
With 30 years of innovation and more than 2,000 installations around the globe, Sectra is a leading imaging IT provider to health systems worldwide. Sectra offers a complete enterprise solution comprised of imaging modules (radiology, cardiology, pathology, orthopedics, and ophthalmology), and a robust VNA. For more information, visit Sectra's website.
Back to HCB News
